Decision: Favourable

Decisions Table

Study Title:

A Phase 3, Randomized, Double-blind, Placebo-controlled Study of Atrasentan in Patients with IgA Nephropathy at Risk of Progressive Loss of Renal Function (The ALIGN Study)

  • NREC Code:

    21-NREC-CT-174

  • Decision:

    Favourable

  • Meeting Date:

    12/01/2022

  • Study Type:

    CT application

  • Principal Investigator:

    Dr Michelle Marie O'Shaughnessy

  • PI Institution:

    Cork University Hospital

  • Sponsor:

    Biotech company

Scroll to Top